Alternative substitutions of N332 in HIV-1AD8 gp120 differentially affect envelope glycoprotein function and viral sensitivity to broadly neutralizing antibodies targeting the V3-glycan
Jeffy J, Parthasarathy D, Ahmed S, Cervera-Benet H, Xiong U, Harris M, Mazurov D, Pickthorn S, Herschhorn A. Alternative substitutions of N332 in HIV-1AD8 gp120 differentially affect envelope glycoprotein function and viral sensitivity to broadly neutralizing antibodies targeting the V3-glycan. MBio 2024, 15: e02686-23. PMID: 38470051, PMCID: PMC11005340, DOI: 10.1128/mbio.02686-23.Peer-Reviewed Original ResearchConceptsHIV-1 strainsHIV-1V3-glycanEnv antigensHIV-1 infection <i>inNeutralizing antibodiesHost CD4<sup>+</sup> T cellsCirculating HIV-1 strainsEnvelope glycoproteinCD4<sup>+</sup> T cellsHuman immunodeficiency virus type IHIV-1 envelope glycoproteinBlock HIV-1 infectionHIV-1 Env trimerHIV-1 isolatesHIV-1 infectionGp120 V3 loopTarget of neutralizing antibodiesHIV-1 entryCell surface expressionLevels of cell surface expressionSensitivity to antibodiesN332 glycanSoluble CD4Gp120 shedding